CSLLY
CSL Limited OTC Listed Dec 29, 2009$21.84
Mkt Cap $84.6B
52w Low $21.61
1.0% of range
52w High $44.85
50d MA $24.40
200d MA $30.78
P/E (TTM)
57.4x
EV/EBITDA
31.7x
P/B
4.0x
Debt/Equity
0.6x
ROE
7.3%
P/FCF
60.3x
RSI (14)
—
ATR (14)
—
Beta
0.22
50d MA
$24.40
200d MA
$30.78
Avg Volume
476.6K
About
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunod…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 8, 2026 | AMC | — | 0.06 | — | — | — | — | — | — | — | — | — |
| Feb 11, 2025 | AMC | — | 0.52 | — | 40.48 | -4.4% | -0.3% | -0.3% | -0.2% | +2.1% | +3.0% | — |
| Oct 30, 2024 | AMC | — | 2.03 | — | 47.48 | -1.3% | -1.3% | -2.1% | -1.2% | -0.3% | -1.1% | — |
| Aug 13, 2024 | AMC | — | 0.19 | — | 49.32 | +2.5% | +1.3% | +1.6% | +3.2% | +5.9% | +5.1% | — |
| Apr 11, 2024 | AMC | — | 0.76 | — | 45.75 | -0.0% | +0.0% | -2.2% | -4.0% | -3.9% | -5.0% | — |
| Feb 13, 2024 | AMC | — | 1.95 | — | 44.96 | -1.0% | +1.4% | +3.5% | +3.0% | +2.8% | +3.1% | — |
| Jun 30, 2023 | AMC | — | 0.15 | — | 46.13 | +0.3% | +0.4% | -1.3% | -3.3% | -3.6% | -4.3% | — |
| Mar 31, 2023 | AMC | — | 0.59 | — | 48.20 | +0.9% | +1.6% | +1.8% | +2.5% | +4.4% | +3.9% | — |
| Dec 31, 2022 | AMC | — | 0.43 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2022 | AMC | — | 1.70 | — | 45.63 | +0.8% | +1.8% | +3.2% | +3.2% | +1.7% | -0.3% | — |
Data updated apr 28, 2026 5:57am
· Source: massive.com